Symptômes négatifs de la schizophrénie : de l’électrophysiologie à l’électrothérapie

Micoulaud-Franchi, Jean-Arthur; Quilès, Clélia; Belzeaux, Raoul; Adida, M.; Jm, Azorin

doi:10.1016/s0013-7006(16)30011-2

Cited by 3 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, some medical devices, using approaches such as deep transcranial magnetic stimulation and transcranial direct current stimulation, are also under investigation for the treatment of negative symptoms. 87,93 While treatments that are eventually determined to be effective all begin with small proof-of-concept studies, early success does not guarantee efficacy in later stages of development and the efficacy of new drug candidates for the treatment of negative symptoms is still uncertain. 94…”

Section: Treatment Pharmacologic Treatmentmentioning

confidence: 99%

<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>

Correll¹,

Schooler²

2020

NDT

505

347

View full text Add to dashboard Cite

Schizophrenia is frequently a chronic and disabling disorder, characterized by heterogeneous positive and negative symptom constellations. The objective of this review was to provide information that may be useful for clinicians treating patients with negative symptoms of schizophrenia. Negative symptoms are a core component of schizophrenia that account for a large part of the long-term disability and poor functional outcomes in patients with the disorder. The term negative symptoms describes a lessening or absence of normal behaviors and functions related to motivation and interest, or verbal/emotional expression. The negative symptom domain consists of five key constructs: blunted affect, alogia (reduction in quantity of words spoken), avolition (reduced goal-directed activity due to decreased motivation), asociality, and anhedonia (reduced experience of pleasure). Negative symptoms are common in schizophrenia; up to 60% of patients may have prominent clinically relevant negative symptoms that require treatment. Negative symptoms can occur at any point in the course of illness, although they are reported as the most common first symptom of schizophrenia. Negative symptoms can be primary symptoms, which are intrinsic to the underlying pathophysiology of schizophrenia, or secondary symptoms that are related to psychiatric or medical comorbidities, adverse effects of treatment, or environmental factors. While secondary negative symptoms can improve as a consequence of treatment to improve symptoms in other domains (ie, positive symptoms, depressive symptoms or extrapyramidal symptoms), primary negative symptoms generally do not respond well to currently available antipsychotic treatment with dopamine D 2 antagonists or partial D 2 agonists. Since some patients may lack insight about the presence of negative symptoms, these are generally not the reason that patients seek clinical care, and clinicians should be especially vigilant for their presence. Negative symptoms clearly constitute an unmet medical need in schizophrenia, and new and effective treatments are urgently needed.

show abstract

Section: Treatment Pharmacologic Treatmentmentioning

confidence: 99%

<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>

Correll¹,

Schooler²

2020

NDT

505

347

View full text Add to dashboard Cite

show abstract

“…MBI has been shown to modulate the levels of cytokines (Shen et al, 2020). In addition, neuroimaging evidence has shown that decreased activity in the prefrontal cortex was associated with negative symptoms of schizophrenia, which can be improved by enhanced prefrontal cortex activity (Micoulaud Franchi, Quiles, Belzeaux, Adida, & Azorin, 2015). MBI has been shown to activate the prefrontal cortex (Sperduti, Martinelli, & Piolino, 2012).…”

Section: Discussionmentioning

confidence: 99%

Mindfulness-based intervention improves residual negative symptoms and cognitive impairment in schizophrenia: a randomized controlled follow-up study

Shen

Zhang

et al. 2021

Psychol. Med.

View full text Add to dashboard Cite

Background Residual negative symptoms and cognitive impairment are common for chronic schizophrenia patients. The aim of this study was to investigate the efficacy of a mindfulness-based intervention (MBI) on negative and cognitive symptoms of schizophrenia patients with residual negative symptoms. Methods In this 6-week, randomized, single-blind, controlled study, a total of 100 schizophrenia patients with residual negative symptoms were randomly assigned to the MBI or control group. The 6-week MBI group and the control group with general rehabilitation programs maintained their original antipsychotic treatments. The scores for the Positive and Negative Syndrome Scale (PANSS), the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and the Symptom Checklist 90 (SCL-90) were recorded at baseline and week 6 to assess psychotic symptoms, cognitive performance, and emotional state, respectively. Results Compared with general rehabilitation programs, MBI alleviated the PANSS-negative subscore, general psychopathology subscore, and PANSS total score in schizophrenia patients with residual negative symptoms (F = 33.77, pBonferroni < 0.001; F = 42.01, pBonferroni < 0.001; F = 52.41, pBonferroni < 0.001, respectively). Furthermore, MBI improved RBANS total score and immediate memory subscore (F = 8.80, pBonferroni = 0.024; F = 11.37, pBonferroni = 0.006), as well as SCL-90 total score in schizophrenia patients with residual negative symptoms (F = 18.39, pBonferroni < 0.001). Conclusions Our results demonstrate that MBI helps schizophrenia patients with residual negative symptoms improve clinical symptoms including negative symptom, general psychopathology symptom, and cognitive impairment. Trial registration ChiCTR2100043803.

show abstract

Evidence-based umbrella review of cognitive effects of prefrontal tDCS

Farhat

Carvalho

Solmi

et al. 2020

Social Cognitive and Affective Neuroscience

View full text Add to dashboard Cite

Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation approach which has been increasingly used as an investigational tool in neuroscience. In social and affective neuroscience research, the prefrontal cortex has been primarily targeted, since this brain region is critically involved in complex psychobiological processes subserving both ‘hot’ and ‘cold’ domains. Although several studies have suggested that prefrontal tDCS can enhance neuropsychological outcomes, meta-analyses have reported conflicting results. Therefore, we aimed to assess the available evidence by performing an umbrella review (UR). We evaluated the effects of prefrontal active vs. sham tDCS on different domains of cognition among healthy and neuropsychiatric individuals. AMSTAR-2 was employed to evaluate the quality of systematic reviews and meta-analyses and the GRADE system was employed to grade the quality of evidence. PubMed/MEDLINE, PsychINFO and the Cochrane Database of Systematic Reviews were searched, and 11 meta-analyses were included resulting in 55 comparisons. Only 16 comparisons reported significant effects favoring tDCS, but 13 of them had either a very low or low quality of evidence. Systematic reviews were rated as having critically low and low quality. Among several reasons to explain these findings, the lack of consensus and reproducibility in tDCS research is discussed.

show abstract

Symptômes négatifs de la schizophrénie : de l’électrophysiologie à l’électrothérapie

Cited by 3 publications

References 55 publications

<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>

<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>

Mindfulness-based intervention improves residual negative symptoms and cognitive impairment in schizophrenia: a randomized controlled follow-up study

Evidence-based umbrella review of cognitive effects of prefrontal tDCS

Contact Info

Product

Resources

About